NEW YORK (GenomeWeb News) – DiaGenic today said that it has licensed biomarkers for mild cognitive impairment to drug firm Merz Pharmaceuticals, which will use the biomarkers for recruiting patients for Alzheimer's disease drug trials.

Frankfurt am Main, Germany-based Merz also has an option to license non-exclusive rights to further biomarkers, under terms of the agreement. Financial details and further terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.